The INHBE Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the CAL-27 oral squamous cell carcinoma line, with targeted disruption of the INHBE gene to establish a loss-of-function model. This heterogeneous pool of knockout cells preserves the genetic background of the parental line while eliminating the encoded inhibin beta E protein, enabling studies of gene function without clonal bias. The polyclonal format is particularly suitable for assays requiring a representative distribution of editing events across the cell population.
The CAL-27 cell line, isolated from a human tongue squamous cell carcinoma, is a widely utilized epithelial model for oral cancer research. These cells display characteristic features of squamous cell carcinoma, including deregulated proliferation, migration, and adhesion, and they retain relevant oncogenic mutations and signaling abnormalities. CAL-27 serves as a robust platform for investigating tumor biology, validating tumor suppressor genes, and testing therapeutic compounds in a biologically relevant context.
INHBE encodes inhibin beta E, a TGF-?? superfamily ligand that forms heterodimers with the inhibin alpha subunit (INHA) to produce inhibin E, or homodimers as activin E. Signaling occurs through activin type I (ACVR1B) and type II (ACVR2A) receptors, triggering phosphorylation of SMAD2 and SMAD3. These receptor-activated SMADs complex with SMAD4 to regulate transcription of key targets like CDKN1A/p21 and c-MYC, thereby controlling cell proliferation, apoptosis, and differentiation. The signaling axis is modulated by follistatin (FST), an antagonist that sequesters activins, and intersects with broader TGF-?? pathways through shared SMAD intermediaries.
In CAL-27 oral cancer cells, INHBE-dependent signaling may influence tumor-suppressive or oncogenic phenotypes, including cell cycle arrest, epithelial-mesenchymal transition, and apoptotic resistance. The polyclonal knockout model permits systematic analysis of INHBE’s role in these processes by comparing functional endpoints between edited and wild-type populations. Researchers can employ this system to dissect how inhibin/activin signaling contributes to oral squamous cell carcinoma aggressiveness and to identify potential vulnerabilities that arise from INHBE loss.
This product is designed for diverse applications such as transcriptomic profiling via RNA-seq or RT-qPCR, phospho-signaling analysis through Western blotting for SMAD2/3 and its phosphorylated forms, and functional assays including MTT/BrdU proliferation, Transwell migration, and Annexin V/PI apoptosis detection. The cells enable drug sensitivity screening and pathway dependency studies in the absence of INHBE. For additional information, researchers may contact Ascent Research.
